The treatment goal for patients with early-stage lung cancer is cure. Multidisciplinary
discussions of surgical resectability and medical operability determine the modality of …

Cisplatin-based adjuvant chemotherapy remains the standard of care for patients with
resected stage II or III non–small-cell lung cancer. However, biomarker-informed clinical …

Background Non-small-cell lung cancer (NSCLC) is terminal in most patients with locally
advanced stage disease. We aimed to assess the antitumour activity and safety of …

Background Approximately 25% of all patients with non-small-cell lung cancer present with
resectable stage IB–IIIA disease, and although perioperative chemotherapy is the standard …

PURPOSE For patients with resectable stage IIIA (N2) non–small-cell lung cancer,
neoadjuvant chemotherapy with cisplatin and docetaxel followed by surgery resulted in a 1 …

Introduction Programmed death receptor-1 (PD-1) inhibitors have shown efficacy in first-line
treatment of NSCLC; however, evidence of PD-1 inhibitor as neoadjuvant treatment is …

Currently, there is no established guidance on how to process and evaluate resected lung
cancer specimens after neoadjuvant therapy in the setting of clinical trials and clinical …

Despite the rapidly evolving treatment landscape in advanced non-small-cell lung cancer
(NSCLC), developments in neoadjuvant and adjuvant treatments have been nascent by …

Immune-checkpoint inhibitors (ICI) have transformed oncological therapy. Up to 20% of all
non-small cell lung cancers (NSCLCs) show durable responses upon treatment with ICI …

Great advances in immune checkpoint blockade have resulted in a paradigm shift in patients
with lung cancer. Immune-checkpoint inhibitor (ICI) treatment, either as monotherapy or …